The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer TreatmentAssignment
Abstract
Active surveillance (AS) is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have completed the goals articulated in the Statement of Work. For specific aim 1,new prostate cancer TMAs have been constructed using specimens from patients treated at Roswell Park. TMAs have been obtained from PCaP. These TMAs have been immunostained for pThoc1, and the immunostaining scored. pThoc1 levels did correlate with some clinical variables, but not others. Immunostaining did not exhibit racial disparities when controlled for disease aggressiveness. For aim 2, prostate cancer specimens have been obtained from patients enrolled on active surveillance, and retrospective specimens have been obtained from PCaP for patients who would have been eligible for active surveillance. These specimens have been immunostained for pThoc1 andpThoc1 levels analyzed. pThoc1 levels did correlate with some clinical variables, but not others. For aim 3, ELISA assays for pThoc1protein and pThoc1 autoantibodies have been developed and used to assay serum samples from prostate cancer patients. pThoc1autoantibody levels are elevated in the serum of prostate cancer patients relative to the serum of healthy control donors. pThoc1autoantibody levels correlate with some clinical variables but not others. Overall findings suggest pThoc1 levels tend to correlate with prostate cancer aggressiveness, but these correlations do not reach statistical significance in some cases.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2018
- Accession Number
- AD1094628
Entities
People
- David W Goodrich